Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Pharmavite veteran to lead Cyanotech

You may also be interested in...



Incoming CHPA Head Melville Brings Pharma Resume To OTC Learning Curve

The Consumer Healthcare Products Association's next president, Scott Melville, says his Rx manufacturing and distribution experience provides a foundation for "navigating a complex regulatory structure" in his first position on the OTC side of the drug industry.

People In Brief

Cyanotech dubs Rosenthal interim president: Cyanotech Corp. appoints David I. Rosenthal to serve as president and CEO as the firm seeks a permanent replacement for Andrew H. Jacobson. In a March 1 release, the Hawaii-based functional ingredient firm says Rosenthal has served on the board since November 2000 and most recently was chief financial officer of specialty food and gift product provider Hickory Farms. The board removed Jacobson from the post but did not elaborate on its reasons. According to the firm's Web site, Jacobson succeeded Gerald R. Cysewski as president and CEO in March 2008. Cysewski, who founded Cyanotech in 1983 and is credited with commercializing the large-scale production of microalgae, stayed on as executive VP and chief scientific officer as Jacobson focused on developing a marketing-oriented approach for enhancing the value of the firm's products

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel